Clinical Trial Results:
ESTUDIO FASE II, MULTICÉNTRICO, ABIERTO, NO RANDOMIZADO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE CETUXIMAB (ERBITUX®) EN COMBINACIÓN CON OXALIPLATINO Y CAPECITABINA (XELOX) DURANTE 12 SEMANAS SEGUIDO DE UN TRATAMIENTO DE MANTENIMIENTO CON CETUXIMAB MÁS CAPECITABINA COMO TRATAMIENTO DE PRIMERA LÍNEA EN PACIENTES ANCIANOS CON CÁNCER COLORRECTAL METASTÁTICO.
Summary
|
|
EudraCT number |
2006-007062-11 |
Trial protocol |
ES |
Global completion date |
21 Aug 2008
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Apr 2019
|
First version publication date |
24 Apr 2019
|
Other versions |
|
Summary report(s) |
TTD0605_Synopsis_Final |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.